We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Sartorius Stedim Biotech and G-Con Global Collaboration to Support Faster, More Flexible Biopharmaceutical Facility Construction

By LabMedica International staff writers
Posted on 13 Feb 2012
Sartorius Stedim Biotech (SSB; Goettingen, Germany) and G-Con (College Station, TX, USA) have agreed to collaborate globally to offer highly advanced and flexible production platforms for the biopharmaceutical manufacturing industry. More...
The new product line will utilize G-Con Manufacturing’s novel modular, mobile clean-room pods and Sartorius Stedim Biotech’s well-established broad single-use and reusable product range to create a totally integrated production process platform.

SSB has integrated its products into unit operations for media/buffer preparation, seed fermentation, cell cultivation and harvesting, ultra-diafiltration, membrane chromatography, and viral clearance for biopharmaceutical development and manufacturing. Combining SSB’s technology with G-Con’s modular, scalable, and flexible pod platform will provide the biopharmaceutical manufacturing industry with an unparalleled set of cost-effective, plug and play tools for next-generation manufacturing facilities.

Maik Jornitz, SSB’s senior vice president of marketing for bioprocess solutions, stated, “The combined product portfolio will fundamentally change the way biopharmaceutical manufacturing processes will be designed and configured. Our integrated solutions unit will implement G-Con’s platform of modular clean-room systems into their designs. In addition, our teams will benefit from G-Con’s engineering and design expertise. Our vision is to create standardized unit operations, implemented into the self-contained G-Con modules. These modules can be used as individual process units or joined to an entire process.”

Barry Holtz, president of G-Con Manufacturing, stated, “Our common goal is to combine our complementary expertise to develop revolutionary solutions for the next-generation of flexible, single-use manufacturing concepts. We couldn’t be more excited about having an agreement with a leader in single-use products like Sartorius Stedim Biotech.”

Effective immediately, G-Con’s modular containment units are available through SSB’s integrated solutions unit and will be rolled out globally in early 2012.

Mr. Jornitz commented, “We do not want to delay the availability of the G-Con units and therefore decided to have our integrated solutions unit utilize the containment systems and G-Con’s engineering capabilities now. The global launch through our sales organizations will follow.”

Sartorius Stedim Biotech is a provider of equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management, and lab technologies are supporting the biopharmaceutical industry worldwide to develop and produce drugs safely, timely, and cost-effectively.

Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is focused on transforming science into solutions.

Headquartered in Aubagne, France, Sartorius Stedim Biotech’s manufacturing, and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany.

G-Con enables developing technologies by significantly lowering the expense and complexity of manufacturing biologic materials to good manufacturing practice (GMP) standards. The G-Con pod solution is completely self-contained and simple to maintain, reducing the need for sophisticated and expansive purpose-built facilities and specialized maintenance. Moreover, G-Con pods can be custom built in a fraction of the time required for a traditional facility and at significantly less cost. G-Con maintains an integrated product team of engineers with bioprocess development, mechanical, electrical, and heating, ventilation, and air conditioning experience combined with a regulatory and quality management system that is qualified to deliver on every size of GMP project.

Related Links:

Sartorius Stedim Biotech
G-Con


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.